BAX
BAXTER INTERNATIONAL INCEvidence as of 2026-09-02Overview · BAXTER INTERNATIONAL INC
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy comp…
Management team
- Mr. Alok Sonig B.E., Mba · Executive VP & Group President of PharmaceuticalsFind on LinkedIn
- Mr. Jose E. Almeida · AdvisorFind on LinkedIn
- Ms. Heather Knight · Executive Vice President & COOFind on LinkedIn
- Mr. Joel T. Grade · Executive VP & CFOFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The desk’s evidence balance is Mixed (+0.3 of a possible +2; was +0.3 before debate) with high confidence. Revenue rose from USD 2,625,000,000 in fiscal Q1 2026 (fiscal quarter ended 2026-04-24) to USD 2,960,000,000 in fiscal Q2 2026 (fiscal quarter ended 2026-07-23), an increase of USD 335,000,000. Gross profit increased from USD 861,000,000 to USD 1,032,000,000 across those quarters, lifting gross margin from about 32.8% to about 34.9%.
Operating income rose meaningfully from USD 58,000,000 to USD 217,000,000 while reported net income was unchanged at USD 126,000,000 in both quarters. Cash and cash equivalents increased from USD 2,017,000,000 as of 2026-03-31 to USD 2,150,000,000 as of 2026-06-30, and weighted-average diluted shares edged up from 515,000,000 to 518,000,000 (reported common shares outstanding moved from 516,469,008 as of 2026-04-24 to 516,995,999 as of 2026-07-23).
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue increased from USD 2,625,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31) to USD 2,960,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30), a quarter-over-quarter rise of USD 335,000,000.
XBRL companyfacts · 0001628280-26-028962Gross profit rose from USD 861,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31) to USD 1,032,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30); gross margin (gross profit divided by revenue) moved from about 32.8% (861 / 2,625) in Q1 2026 to about 34.9% (1,032 / 2,960) in Q2 2026.
XBRL companyfacts · 0001628280-26-028962Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
On August 18, 2026 (filed August 19, 2026), Baxter International Inc. appointed John Rogers as Executive Vice President and Chief Financial Officer effective October 1, 2026.
8-K filed 2026-08-19The Offer Letter filed August 18, 2026 (filed August 19, 2026) sets Mr. Rogers's annual base salary at $925,000 and a target annual bonus opportunity equal to 100% of his base salary, with eligibility for a prorated bonus for 2026.
8-K filed 2026-08-19Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the past 6 months is +34.0% and ranks in the 90th percentile of the 547-stock research universe on 2026-09-01.
Moneyta signal set · 2026-09-01weakened in debateMomentum measured as 12_1 is +30.2% and ranks in the 71th percentile of the 547-stock research universe on 2026-09-01.
Moneyta signal set · 2026-09-01weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T01:55:42.883348+00:00, BAX represented 0.32% of the ETF XLV by fund weight.
ETF constituents · market dataAs of 2026-09-02T01:55:23.601495+00:00, BAX represented 0.18% of the ETF VO by fund weight.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Baxter announced a CFO transition in headlines on 31–Sept 2026 that names John Rogers as the next Chief Financial Officer and Executive Vice President and notes interim assignments to other finance roles.
News · simplywall.st · 2026-09-02Coverage highlights a broader finance leadership reset and balance-sheet actions for Baxter in an article published 2026-08-31.
News · simplywall.st · 2026-08-31Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
Free cash flow for the trailing twelve months is $7,000,000.
Valuation inputs · SEC XBRL + stored EOD closeThe price-to-free-cash-flow (P/FCF) multiple is 1,885.52 and free cash flow per share is $0.0135.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several contemporaneous company-level signals in the record support a favorable read: quarter-over-quarter revenue, gross profit, and operating income all rose between Q1 and Q2 2026 while cash balances increased, indicating improving core operating performance and liquidity. Recent corporate actions — a named CFO appointment with structured compensation and performance-based equity, plus press coverage citing a finance leadership reset and balance-sheet actions — reinforce management attention on financial stewardship and deleveraging. Market technicals show strong positive momentum (6‑ and 12‑month rankings) and a golden cross, and there are new institutional purchases reported alongside coverage framing Baxter as a turnaround candidate. These points together provide moderately strong evidence that company-specific fundamentals and governance developments underpin recent positive market interest, even though valuation and historical drawdown metrics remain weak on the record.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.40
37 surviving claims rest on 12 distinct sources; the heaviest analyst carries 19% of them, and 97% of what the desk raised survived the debate.
The evidence set is moderately robust: 37 surviving claims draw on a dozen distinct sources and most desk challenges did not overturn the read, which increases confidence in the internal consistency of the narrative. However, a single analyst accounts for a sizeable share of claims and filings/computed signals are heavily used, so the read is somewhat sensitive to source-concentration and analyst-dependence risk — treat specific or novel inferences as weaker than claims directly traceable to primary filings.
Peer context · computed, not argued
12-1 momentum ranks 1st of 3 in Medical Instruments & Supplies (as of 2026-09-01).
90-day volatility ranks 1st of 3 in Medical Instruments & Supplies (as of 2026-09-01).
dividend yield ranks 2nd of 3 in Medical Instruments & Supplies (as of 2026-09-01).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
14 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.4 to the score
3 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+1.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.3 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on BAX Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.